The weekly litigation news digest is live. Subscribe now
Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt - EP3995135
The patent EP3995135 was granted to Grnenthal on Jul 13, 2022. The application was filed on Nov 10, 2020 under application number EP20206800A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3995135
- Application Number
- EP20206800A
- Filing Date
- Nov 10, 2020
- Status
- Granted And Under Opposition
- Jun 10, 2022
- Publication Date
- Jul 13, 2022
- External Links
- Slate, Register, Google Patents
Patent Summary
Tablet providing a prolonged release of tapentadol, where tapentadol is in the form of a salt with tartaric acid, in particular L-(+)-tartaric acid. The tablet is made by applying a compressive force to a powder and consolidating the powder into a compacted form in the die of a press.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (19) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents